“We have been delighted to work with DKSH since our initial partnership began earlier this year,” said Mark Levick, chief executive officer, Alvotech. “The partnership is designed to accelerate improved patient access for high quality biosimilar medicines in the Asian biosimilar industry. This is also another milestone for Alvotech, where we continue to extend our network of leading commercial partners around the globe.”
In March 2020, the companies announced its exclusive partnership agreement for AVT02, an adalimumab biosimilar, a leading drug indicated for the treatment of several autoimmune diseases. The collaboration includes the following markets: Taiwan, Korea, Hong Kong, Philippines, Vietnam, Thailand, Cambodia, Myanmar, Malaysia, Singapore, Indonesia, India, Bangladesh and Pakistan. These biosimilar candidates’ brand values are estimated around $1.5 billion in annual sales in the Asia Pacific region, according to IQVIA data.
Bijay Singh, global head of business unit healthcare, DKSH, said, “The extended partnership with Alvotech demonstrates our commitment to bringing high-quality medical products to Asian patients and enriching their lives. At DKSH, we believe biosimilars offer a tremendous opportunity to enhance the standard of care in several disease areas across the Asian markets. This partnership brings together two strong players—Alvotech, with their leading position in the development and manufacturing of biosimilars worldwide, and DKSH as the leading commercial outsourcing partner for healthcare companies in Asia.”
This latest announcement from Alvotech and DKSH expands on a deep partnership between the two companies to accelerate the introduction of high quality biosimilar to patients in Asia. In the last twelve months, Alvotech has made strategic partnership agreements with leading regional and global industry players including: Teva in the U.S., Stada in Europe, JAMP in Canada, Yas Holding in the Middle East and Fuji Pharma in Japan.